|
1
|
Zhou C and Yao LD: Strategies to improve
outcomes of patients with EGRF-mutant non-small cell lung cancer:
Review of the literature. J Thorac Oncol. 11:174–186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang H, Gao L, Zhang B, Zhang L and Wang
C: Prognostic value of platelet to lymphocyte ratio in non-small
cell lung cancer: A systematic review and meta-analysis. Sci Rep.
6:226182016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao S, Jiang T, Zhang L, Yang H, Liu X,
Jia Y and Zhou C: Clinicopathological and prognostic significance
of regulatory T cells in patients with non-small cell lung cancer:
A systematic review with meta-analysis. Oncotarget. 7:36065–36073.
2016.PubMed/NCBI
|
|
4
|
Tomos I, Vlami A, Karakatsani A, Korbila
I, Manali ED and Papiris SA: Diffuse idiopathic skeletal
hyperostosis (DISH) and non small cell lung cancer: Case
presentation and review of the literature. Pneumonol Alergol Pol.
84:116–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van der Wekken AJ, Saber A, Hiltermann TJ,
Kok K, van den Berg A and Groen HJ: Resistance mechanisms after
tyrosine kinase inhibitors afatinib and crizotinib in non-small
cell lung cancer, a review of the literature. Crit Rev Oncol
Hematol. 100:107–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folch E, Costa DB, Wright J and VanderLaan
PA: Lung cancer diagnosis and staging in the minimally invasive age
with increasing demands for tissue analysis. Transl Lung Cancer
Res. 4:392–403. 2015.PubMed/NCBI
|
|
7
|
Ju F, Lee HK, Osarogiagbon RU, Yu X, Faris
N and Li J: Computer modeling of lung cancer diagnosis-to-treatment
process. Transl Lung Cancer Res. 4:404–414. 2015.PubMed/NCBI
|
|
8
|
Khan M, Wasim A, Mirrakhimov AE, McMahon
BA, Judge DP, Chu LC, Banavali A and Zeidan AM: Case report of a
patient with left ventricular assistance device undergoing
chemotherapy for a new diagnosis of lung cancer. Case Rep Oncol
Med. 2015:1637272015.PubMed/NCBI
|
|
9
|
Kim HS, Lee KS, Ohno Y, van Beek EJ and
Biederer J: PET/CT versus MRI for diagnosis, staging, and follow-up
of lung cancer. J Magn Reson Imaging. 42:247–260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blumenthal GM, Karuri SW, Zhang H, Zhang
L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P and Pazdur
R: Overall response rate, progression-free survival, and overall
survival with targeted and standard therapies in advanced
non-small-cell lung cancer: US food and drug administration
trial-level and patient-level analyses. J Clin Oncol. 33:1008–1014.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jimenez-Bonilla JF, Quirce R,
Martinez-Rodriguez I, De Arcocha-Torres M, Carril JM and Banzo I:
The role of PET/CT molecular imaging in the diagnosis of recurrence
and surveillance of patients treated for non-small cell lung
cancer. Diagnostics (Basel). 6:E362016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baco E, Rud E, Ukimura O, Vlatkovic L,
Svindland A, Matsugasumi T, Bernhard JC, Rewcastle JC and Eggesbø
HB: Effect of targeted biopsy guided by elastic image fusion of MRI
with 3D-TRUS on diagnosis of anterior prostate cancer. Urol Oncol.
32:1300–1307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krüger S, Mottaghy FM, Buck AK, Maschke S,
Kley H, Frechen D, Wibmer T, Reske SN and Pauls S: Brain metastasis
in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for
diagnosis in the initial staging. Nuklearmedizin. 50:101–106. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li ZL, Chen X, Xia CC, Sun JY, Li CX, Tang
HH and Song B: Comparison of the efficacy of gadobutrol and
multihance in contrast-enhanced MRI for diagnosis of brain
metastasis in lung cancer. Sichuan Da Xue Xue Bao Yi Xue Ban.
43:601–604. 2012.(In Chinese). PubMed/NCBI
|
|
15
|
Freedman M, Chang EH, Zhou Q and Pirollo
KF: Nanodelivery of MRI contrast agent enhances sensitivity of
detection of lung cancer metastases. Acad Radiol. 16:627–637. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Badea CT, Athreya KK, Espinosa G, Clark D,
Ghafoori AP, Li Y, Kirsch DG, Johnson GA, Annapragada A and
Ghaghada KB: Computed tomography imaging of primary lung cancer in
mice using a liposomal-iodinated contrast agent. PloS One.
7:e344962012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pauls S, Mottaghy FM, Schmidt SA, Krüger
S, Möller P, Brambs HJ and Wunderlich A: Evaluation of lung tumor
perfusion by dynamic contrast-enhanced MRI. Magn Reson Imaging.
26:1334–1341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mistry NN, Pollaro J, Song J, De Lin M and
Johnson GA: Pulmonary perfusion imaging in the rodent lung using
dynamic contrast-enhanced MRI. Magn Reson Med. 59:289–297. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eichinger M, Puderbach M, Fink C, Gahr J,
Ley S, Plathow C, Tuengerthal S, Zuna I, Müller FM and Kauczor HU:
Contrast-enhanced 3D MRI of lung perfusion in children with cystic
fibrosis-initial results. Eur Radiol. 16:2147–2152. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lazarev SM, Massard Zh, Reshetov AV,
Nikolaev GV, Volgin GN, Osipov EV, Lomteva EIu, Nokhrin AV and
Kakysheva OE: Role of biological tumor markers CEA, Cyfra-21, NSE,
TU M2-PK in diagnosis and treatment of lung cancer. Vestn Khir Im I
I Grek. 169:39–43. 2010.(In Russian). PubMed/NCBI
|
|
21
|
Wang B, He YJ, Tian YX, Yang RN, Zhu YR
and Qiu H: Clinical utility of haptoglobin in combination with CEA,
NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac J Cancer
Prev. 15:9611–9614. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen CL, Hu GY, Mei Q, Qiu H, Long GX and
Hu GQ: Epidermal growth factor receptor-targeted ultra-small
superparamagnetic iron oxide particles for magnetic resonance
molecular imaging of lung cancer cells in vitro. Chin Med J (Engl).
125:2322–2328. 2012.PubMed/NCBI
|
|
23
|
Preskorn SH, Macaluso M and Trivedi M: How
commonly used inclusion and exclusion criteria in antidepressant
registration trials affect study enrollment. J Psychiatr Pract.
21:267–274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Crinὸ L, Weder W, van Meerbeeck J and
Felip E; ESMO Guidelines Working Group, : Early stage and locally
advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol 21 Suppl. 5:v103–v115. 2010. View Article : Google Scholar
|
|
25
|
Sahibzada I, Batura D and Hellawell G:
Validating multiparametric MRI for diagnosis and monitoring of
prostate cancer in patients for active surveillance. Int Urol
Nephrol. 48:529–533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boehm K, Schiffmann J, Tian Z, Lesmana H,
Larcher A, Mandel P, Karakiewicz PI, Graefen M, Schwarz R, Krüll A
and Tilki D: Five-year biochemical recurrence-free and overall
survival following high-dose-rate brachytherapy with additional
external beam or radical prostatectomy in patients with clinically
localized prostate cancer. Urol Oncol. 34:119.e11–e18. 2016.
View Article : Google Scholar
|
|
27
|
Zhao JJ, Chen J, Wang ZP, Pan J and Huang
YH: Double labeling and comparison of fluorescence intensity and
photostability between quantum dots and FITC in oral tumors. Mol
Med Rep. 4:425–429. 2011.PubMed/NCBI
|
|
28
|
Kargahi N, Razavi SM, Deyhimi P and
Homayouni S: Comparative evaluation of eosinophils in normal
mucosa, dysplastic mucosa and oral squamous cell carcinoma with
hematoxylin-eosin, Congo red, and EMR1 immunohistochemical staining
techniques. Electron Physician. 7:1019–1026. 2015.PubMed/NCBI
|
|
29
|
Ocak I, Bernardo M, Metzger G, Barrett T,
Pinto P, Albert PS and Choyke PL: Dynamic contrast-enhanced MRI of
prostate cancer at 3 T: A study of pharmacokinetic parameters. AJR
Am J Roentgenol. 189:8492007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rappeport ED, Loft A, Berthelsen AK, von
der Recke P, Larsen PN, Mogensen AM, Wettergren A, Rasmussen A,
Hillingsoe J, Kirkegaard P and Thomsen C: Contrast-enhanced
FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients
with liver metastases from colorectal cancer: A prospective study
with intraoperative confirmation. Acta Radiol. 48:369–378. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hatzoglou V, Tisnado J, Mehta A, Peck KK,
Daras M, Omuro AM, Beal K and Holodny AI: Dynamic contrast-enhanced
MRI perfusion for differentiating between melanoma and lung cancer
brain metastases. Cancer Med. 6:761–767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ye ZJ, Qiu HZ, Li PF, Liang MZ, Zhu YF,
Zeng Z, Hu GY, Wang SN and Quan XM: Predicting changes in quality
of life and emotional distress in chinese patients with lung,
gastric, and colon-rectal cancer diagnoses: The role of
psychological resilience. Psychooncology. 26:829–835. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaseda K, Watanabe K, Asakura K, Kazama A
and Ozawa Y: Identification of false-negative and false-positive
diagnoses of lymph node metastases in non-small cell lung cancer
patients staged by integrated (18F-)fluorodeoxyglucose-positron
emission tomography/computed tomography: A retrospective cohort
study. Thorac Cancer. 7:473–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abraha I, Giovannini G, Serraino D, Fusco
M and Montedori A: Validity of breast, lung and colorectal cancer
diagnoses in administrative databases: A systematic review
protocol. BMJ Open. 6:e0104092016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Langen AJ, van den Boogaart V,
Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans
B, Leffers P, Dingemans AM, et al: Monitoring response to
antiangiogenic therapy in non-small cell lung cancer using imaging
markers derived from PET and dynamic contrast-enhanced MRI. J Nucl
Med. 52:48–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nensa F, Stattaus J, Morgan B, Horsfield
MA, Soria JC, Besse B, Gounant V, Khalil A, Seng K, Fischer B, et
al: Dynamic contrast-enhanced MRI parameters as biomarkers for the
effect of vatalanib in patients with non-small-cell lung cancer.
Future Oncol. 10:823–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao W, Yu H, Han Z, Gao N, Xue J and Wang
Y: Clinical significance of joint detection of serum CEA, SCCA, and
bFGF in the diagnosis of lung cancer. Int J Clin Exp Pathol.
8:9506–9511. 2015.PubMed/NCBI
|
|
38
|
Wang P, Piao Y, Zhang X, Li W and Hao X:
The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal
fluid can be useful indicators for diagnosis of meningeal
carcinomatosis of lung cancer. Cancer Biomark. 13:123–130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu X, Madhankumar AB, Miller PA, Duck KA,
Hafenstein S, Rizk E, Slagle-Webb B, Sheehan JM, Connor JR and Yang
QX: MRI contrast agent for targeting glioma: Interleukin-13 labeled
liposome encapsulating gadolinium-DTPA. Neuro Oncol. 18:691–699.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Z, Qutaish M, Han Z, Schur RM, Liu Y,
Wilson DL and Lu ZR: MRI detection of breast cancer micrometastases
with a fibronectin-targeting contrast agent. Nat Commun.
6:79842015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Y, Zhou J and Yu K: Design,
synthesis, and in vitro evaluation of a binary targeting MRI
contrast agent for imaging tumor cells. Amino Acids. 46:449–457.
2014. View Article : Google Scholar : PubMed/NCBI
|
